MedPath

Changing sleep timing to improve glucose metabolism

Not Applicable
Conditions
Prevention of diabetes for people with social jetlag
Nutritional, Metabolic, Endocrine
Registration Number
ISRCTN11967109
Lead Sponsor
Amsterdam UMC Location VUmc
Brief Summary

2024 Protocol article in https://pubmed.ncbi.nlm.nih.gov/38997765/ (added 16/07/2024)

Detailed Description

Not available

Recruitment & Eligibility

Status
Ongoing
Sex
All
Target Recruitment
60
Inclusion Criteria

1. Social jetlag (>1h) (calculated as difference between midpoint of sleep during week days and free weekend days)
2. (Pre) diabetes: HbA1c >39 mmol/mol (5.7%), fasting plasma glucose >5.6 mmol/l, or 2-hour OGTT >7.8mmol/l (according to the American Diabetes Association) including the use of any glucose-lowering medication
3. Informed consent to be contacted for future research
4. Willing to comply with the study procedures

Exclusion Criteria

1. Excessive alcohol use (>21 alcoholic consumptions per week);
2. Having crossed more than 1 time zone in the month prior to participation;
3. Working shifts more than once per month;
4. Unable to provide written informed consent;
5. Visually impaired;

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Glycemic control measured as HbA1c levels comparing the intervention and control group in an<br>intention to treat analysis at baseline after 12 weeks.<br>
Secondary Outcome Measures
NameTimeMethod
All outcomes will be measured over the duration of 3 weeks and 12 weeks:<br>1. Other glycemic measures: fasting blood glucose and insulin levels, medication use and frequency of hypoglycemic sensation;<br>2. Metabolic outcomes, including BMI, waist, blood pressure, fat percentage, (para)sympathetic nervous system activity from ECGs and electrochemical skin conductance tests,<br>3. Sleep measured as sleep times, sleep quality and sleep phases using a sleep measuring Headband (only after 3 weeks);<br>4. Mood including depression, fatigue and anxiety measured using questionnaires<br>5. Quality of life measured using the EQ5D questionnaire.<br>6. Additionally, to assess other factors that might play a role (possible mediators), we will assess the Dim Light Melatonin Onset (DLMO) in saliva samples (in a subgroup), feeling of satiety and satiation is assessed using a 10-cm VAS scale and physical activity using an accelerometer.
© Copyright 2025. All Rights Reserved by MedPath